Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial LANCET HAEMATOLOGY Diefenbach, C. S., Hong, F., Ambinder, R. F., Cohen, J. B., Robertson, M. J., David, K. A., Advani, R. H., Fenske, T. S., Barta, S. K., Palmisiano, N. D., Svoboda, J., Morgan, D. S., Karmali, R., Sharon, E., Streicher, H., Kahl, B. S., Ansell, S. M. 2020; 7 (9): E660–E670
View details for Web of Science ID 000564050500017